|
04.12.2024 13:29:26
|
Stoke Therapeutics Receives Breakthrough Therapy Designation For Zorevunersen
(RTTNews) - Stoke Therapeutics (STOK) announced that it has received Breakthrough Therapy Designation from the FDA for zorevunersen for the treatment of Dravet syndrome with a confirmed mutation, not associated with gain-of-function, in the SCN1A gene. The company said discussions with the FDA and other global regulatory agencies regarding a global, randomized, controlled Phase 3 registrational study of zorevunersen continue to progress. The company plans to provide an update on Phase 3 registrational plans by the end of the year.
Zorevunersen is being developed as potentially the first disease-modifying medicine for the treatment of Dravet syndrome.
For More Such Health News, visit rttnews.com.
Analysen zu Stoke Therapeutics Inc Registered Shs
Jahresrückblick & Jahresausblick 2024/2025 – Wall Street Live mit Tim Schäfer
In unserem zweiwöchigen Format „Wall Street Live“ mit Tim Schäfer behandeln wir Topaktuelle Themen des Marktgeschehens.
👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| Stoke Therapeutics Inc Registered Shs | 11.28 | -0.44% |
|
Meistgelesene Nachrichten
Börse aktuell - Live Ticker
Vorweihnachtliche Zurückhaltung: SMI schlussendlich im Plus -- DAX geht schwächer aus dem HandelDer heimische Aktienmarkt schloss am Montag im Plus, wohingegen sich der deutsche Aktienmarkt abwärts bewegte.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |